Hot topics

Continuing to Follow the Science: An Open Letter from Pfizer Chairman and CEO Dr. Albert Bourla
Continuing to Follow the Science: An Open Letter from…
Last December, Pfizer and our collaborator, BioNTech, achieved…
Continuing to Follow the Science
Pfizer Opens 2021 Call for Proposals for Pre-Clinical Collaboration
Pfizer Opens 2021 Call for Proposals for Pre-Clinical…
Pfizer Opens 2021 Call for Proposals for Pre-Clinical…
Pfizer Opens 2021 Call for…
Why Pfizer Opposes the TRIPS Intellectual Property Waiver for COVID-19 Vaccines
An Open Letter from Pfizer Chairman and CEO to Colleagues
An Open Letter from Albert Bourla to Pfizer Employees   Dear…
An Open Letter from Pfizer…
New Discoveries in Metastatic Breast Cancer Can’t Wait: How Independent Scientific Research is Moving Forward Patient Care
New Discoveries in Metastatic Breast Cancer Can’t Wait: How…
Until the 20th century, breast cancer was considered an…
New Discoveries in Metastatic…
Covid Vaccine Study - What's Next
Our COVID-19 Vaccine Study – What’s Next?
Pfizer Submitted an EUA Request for Its COVID-19 Vaccine - What’…
Our COVID-19 Vaccine Study – What…
Scientists_Image_380X220.jpg
Albert Bourla Discusses Our FDA Submission
Albert Bourla Discusses Our FDA…
Albert Update
UPDATE: ALBERT BOURLA DISCUSSES COVID-19 VACCINE EFFICACY…
I am happy to share with you that Pfizer and our collaborator,…
COVID-19 VACCINE EFFICACY RESULTS
An Open Letter to Our Trial Participants
An Open Letter to COVID-19 Vaccine Trial Participants from…
Dear Participant,
Trial Participant Letter
An Open Letter from Pfizer Chairman and CEO Albert Bourla
An Open Letter from Pfizer Chairman and CEO Albert Bourla
As we get closer to an important data readout from our COVID-19…
Read More